Cargando…

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer

The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is broadly recognized. The earliest methods for enriching CTCs from whole blood rely on antibody-based positive selection. The prognostic utility of CTC enumeration using positive selection with the FDA-ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Groen, Levi, Kloots, Iris, Englert, David, Seto, Kelly, Estafanos, Lana, Smith, Paul, Verhaegh, Gerald W., Mehra, Niven, Schalken, Jack A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218842/
https://www.ncbi.nlm.nih.gov/pubmed/37240349
http://dx.doi.org/10.3390/ijms24109002
_version_ 1785048869766168576
author Groen, Levi
Kloots, Iris
Englert, David
Seto, Kelly
Estafanos, Lana
Smith, Paul
Verhaegh, Gerald W.
Mehra, Niven
Schalken, Jack A.
author_facet Groen, Levi
Kloots, Iris
Englert, David
Seto, Kelly
Estafanos, Lana
Smith, Paul
Verhaegh, Gerald W.
Mehra, Niven
Schalken, Jack A.
author_sort Groen, Levi
collection PubMed
description The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is broadly recognized. The earliest methods for enriching CTCs from whole blood rely on antibody-based positive selection. The prognostic utility of CTC enumeration using positive selection with the FDA-approved CellSearch(TM) system has been demonstrated in numerous studies. The capture of cells with specific protein phenotypes does not fully represent cancer heterogeneity and therefore does not realize the prognostic potential of CTC liquid biopsies. To avoid this selection bias, CTC enrichment based on size and deformability may provide better fidelity, i.e., facilitate the characterization of CTCs with any phenotype. In this study, the recently FDA-approved Parsortix(®) technology was used to enrich CTCs from prostate cancer (PCa) patients for transcriptome analysis using HyCEAD(TM) technology. A tailored PCa gene panel allowed us to stratify metastatic castration-resistant prostate cancer (mCRPC) patients with clinical outcomes. In addition, our findings suggest that targeted CTC transcriptome profiling may be predictive of therapy response.
format Online
Article
Text
id pubmed-10218842
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102188422023-05-27 Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Groen, Levi Kloots, Iris Englert, David Seto, Kelly Estafanos, Lana Smith, Paul Verhaegh, Gerald W. Mehra, Niven Schalken, Jack A. Int J Mol Sci Article The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is broadly recognized. The earliest methods for enriching CTCs from whole blood rely on antibody-based positive selection. The prognostic utility of CTC enumeration using positive selection with the FDA-approved CellSearch(TM) system has been demonstrated in numerous studies. The capture of cells with specific protein phenotypes does not fully represent cancer heterogeneity and therefore does not realize the prognostic potential of CTC liquid biopsies. To avoid this selection bias, CTC enrichment based on size and deformability may provide better fidelity, i.e., facilitate the characterization of CTCs with any phenotype. In this study, the recently FDA-approved Parsortix(®) technology was used to enrich CTCs from prostate cancer (PCa) patients for transcriptome analysis using HyCEAD(TM) technology. A tailored PCa gene panel allowed us to stratify metastatic castration-resistant prostate cancer (mCRPC) patients with clinical outcomes. In addition, our findings suggest that targeted CTC transcriptome profiling may be predictive of therapy response. MDPI 2023-05-19 /pmc/articles/PMC10218842/ /pubmed/37240349 http://dx.doi.org/10.3390/ijms24109002 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Groen, Levi
Kloots, Iris
Englert, David
Seto, Kelly
Estafanos, Lana
Smith, Paul
Verhaegh, Gerald W.
Mehra, Niven
Schalken, Jack A.
Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
title Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
title_full Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
title_fullStr Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
title_full_unstemmed Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
title_short Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
title_sort transcriptome profiling of circulating tumor cells to predict clinical outcomes in metastatic castration-resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218842/
https://www.ncbi.nlm.nih.gov/pubmed/37240349
http://dx.doi.org/10.3390/ijms24109002
work_keys_str_mv AT groenlevi transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT klootsiris transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT englertdavid transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT setokelly transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT estafanoslana transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT smithpaul transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT verhaeghgeraldw transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT mehraniven transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer
AT schalkenjacka transcriptomeprofilingofcirculatingtumorcellstopredictclinicaloutcomesinmetastaticcastrationresistantprostatecancer